Home CUSTOMERS Neoplasma 2022 Neoplasma Vol.69, No.3, p.657–669, 2022

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.69, No.3, p.657–669, 2022

Title: CDC Like Kinase 2 plays an oncogenic role in colorectal cancer via modulating the Wnt/β-catenin signaling
Author: Hai-Bo Zhou, Li Yang, Shi-Fang Liu, Xin-Hua Xu, Zhuo Chen, Yun-Xiao Li, Jin-Hua Yuan, Yong-Chang Wei

Abstract: Colorectal cancer (CRC) is a common malignant tumor with high morbidity and mortality, and significant heterogeneity among patients. In this study, we aimed to explore the role and mechanism of CLK2 in CRC, a kinase that phosphorylates SR proteins involved in splicing. Based on the analysis from The Cancer Genome Atlas (TCGA) dataset and tissue microarray, we found that CLK2 was upregulated in CRC tissues and associated with a higher tumor stage and poorer overall survival. Consistent with the bioinformatics analysis, the functional experiments validated that CLK2 acted as a tumor-promoting factor in CRC progression. CLK2 knockdown suppressed aggressive cell proliferation, migration, and invasion in vitro, as well as restrained tumor growth in vivo. In terms of mechanism, we found that the Wnt/β-catenin signaling pathway was responsible for the CLK2-induced CRC progression, based on the results of pathway enrichment analysis and subsequent experimental validation. Thus, our study, for the first time, identified the role of CLK2 in CRC development and provided a compelling biomarker for targeted therapy in CRC treatment.

Keywords: CLK2; Wnt; β-catenin; prognosis; colorectal cancer
Published online: 16-Mar-2022
Year: 2022, Volume: 69, Issue: 3 Page From: 657, Page To: 669
doi:10.4149/neo_2022_220206N138
Price: 27.30 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.